ライフサイエンスコーパス: anti-idiotype

1 Anti-idiotype 3H1 mimics a distinct and specific epitope

2 ived mature dendritic cells (DC) loaded with anti-idiotype 3H1 or CEA could reverse CEA unresponsiven

3 Here, we have combined the anti-idiotype 3H1 with the CTL peptides of CEA to augmen

4 e sera from 40 of 47 patients showed an anti-anti-idiotype (Ab3) response.

5 Anti-idiotype (anti-Id) antibody can induce tumor dorman

6 We developed a murine monoclonal anti-idiotype (anti-Id) antibody, 3H1, which mimics a sp

7 Tumor-specific anti-idiotype (anti-Id) monoclonal antibodies (MoAbs) to

8 proach that is analogous to the isolation of anti-idiotype antibodies and were able to isolate peptid

9 assay (ELISA) assays for idiotype protein or anti-idiotype antibodies in serum.

10 Anti-idiotype antibodies, in addition to cytotoxic T cel

11 al inactive disease in patients treated with anti-idiotype antibodies.

12 were treated with 52 courses of custom-made anti-idiotype antibodies.

13 characterize the structural footprint of an anti-idiotype antibody (E1) specific for a potent, fully

14 dendritic cells (DCs) pulsed with the murine anti-idiotype antibody 3H1 as a tumor vaccine.

15 s studies suggested that vaccination with an anti-idiotype antibody 3H1, which mimics a specific epit

16 se unconfirmed (CR/CRu) to CVP and making an anti-idiotype antibody are 2 independent factors that ea

17 This material reacts with an anti-idiotype antibody by Western blotting, ELISA, and a

18 The C3d-conjugated anti-idiotype antibody induces a strong idiotype and ant

19 We have reported that anti-idiotype antibody response and FcgammaRIIIa 158 val

20 data demonstrate the utility of employing an anti-idiotype antibody to monitor a patient's specific i

21 ound to inhibit mAb HGAC 39.G3 binding to an anti-idiotype antibody with approximately 1000-fold grea

22 rcinoembryonic antigen (CEA), and that of an anti-idiotype antibody, 3H1, which mimics CEA and can be

23 We generated an anti-idiotype antibody, designated CeaVac, that is an in

24 at binds the same protein and is superior to anti-idiotype approaches.

25 ntibody elicits an anti-antibody response or anti-idiotype, consequently producing a disease-inciting

26 l as the use of photopheresis to generate an anti-idiotype cytotoxic T-cell response.

27 minidase, and three Fab complexes with their anti-idiotype Fabs.

28 phoma based on tumor idiotype (Id) has shown anti-idiotype humoral immune responses in 40%-50% and ce

29 We propose that the anti-idiotype (Id) binds to rituximab molecules bound un

30 jor histocompatibility complex (MHC) II, and anti-idiotype (Id) radiolabeled with 131-iodine.

31 a of multiple donors resulting from idiotype/anti-idiotype (Id/anti-Id) interactions.

32 rall survival of all 20 patients mounting an anti-idiotype immune response are significantly prolonge

33 eeded to prove a causal relationship between anti-idiotype immunity and improved clinical outcome.

34 rified 38C13 scFv generate >10 micrograms/ml anti-idiotype immunoglobulins.

35 PNAG bound together via an apparent idiotype-anti-idiotype interaction.

36 cluding the case previously studied using an anti-idiotype, involvement of the splenic marginal zone

37 with the experimental fact that the level of anti-idiotypes is low in autoimmune patients but high in

38 mAb GH1002 was elicited with the syngeneic anti-idiotype mAb MK2-23 which mimics the determinant de

39 cular adjuvant peptide is crosslinked to the anti-idiotype mimetic by chemical means without modifyin

40 We isolated and characterized an anti-idiotype monoclonal antibody 3H1, which mimics a di

41 Anti-idiotype of (natural) autoantibodies participate in

42 Focusing on an idiotype/anti-idiotype pair embedded in an environment such as th

43 he first detailed molecular comparison of an anti-idiotype paratope specific for a human antibody wit

44 demonstrate that the resultant semisynthetic anti-idiotype peptibodies kill tumor cells in vitro with

45 hybridoma-generated vaccines, we found that anti-idiotype production was even more highly associated

46 olipin antibodies (the latter by an idiotype-anti-idiotype reaction).

47 mmunity through a network involving idiotype-anti-idiotype reactions termed 'autoantigen complementar

48 Although anti-idiotype responses are theoretically possible again

49 reatment with CAMPATH-1H can lead to patient anti-idiotype responses which may be exacerbated by the

50 en subcutaneous alemtuzumab made substantial anti-idiotype responses.

51 st detailed molecular comparison between the anti-idiotype surface and its analogous epitope located

52 The idea is to introduce an antigen or anti-idiotype that binds to the autoantibodies with high

53 ft, the bystander effect, molecular mimicry, anti-idiotype theory, antigenic complementarity, and dua

54 To enhance the immunogenicity of an anti-idiotype vaccine we incorporated a molecular adjuva